$68.4 Million Epidiolex Sales Drive GW Pharma’s $72 Million Revenue in Q2

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019 Epidiolex U.S. Q2 net sales of $68.4 million Positive CHMP opinion clears way for an expected European approval in October  Conference call today at 4:30 p.m. EST  CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc
[Read More ...]

Originally posted on $68.4 Million Epidiolex Sales Drive GW Pharma’s $72 Million Revenue in Q2 via Vic Neufeld Medical Marijuana News